Results 111 to 120 of about 584,093 (236)
Genetic variation influences the pharmacological response to metformin and SGLT2 inhibitors in patients with type 2 diabetes mellitus. Pharmacogenetic biomarkers affecting drug transport, metabolism and target activity contribute to inter‐individual differences in treatment efficacy and adverse effects, supporting the implementation of personalized ...
Imran Hossain +6 more
wiley +1 more source
Modulation of neurosteroid potentiation by protein kinases at synaptic- and extrasynaptic-type GABAA receptors. [PDF]
GABAA receptors are important for inhibition in the CNS where neurosteroids and protein kinases are potent endogenous modulators. Acting individually, these can either enhance or depress receptor function, dependent upon the type of neurosteroid or ...
Adams, JM, Thomas, P, Smart, TG
core
ABSTRACT Background and Aims The prevalence of diabetes mellitus is on the rise globally, presenting a significant challenge to healthcare systems, particularly in developing countries like Bangladesh. However, treatment modalities, care‐seeking attitudes and clinical profiles among these patients are not well explored. This descriptive cross‐sectional
Md. Shamsur Rahman Sweet +4 more
wiley +1 more source
ABSTRACT Objective This study aimed to evaluate the effects of laser photobiomodulation (PBM) using the systemic vascular technique (VPBM) on glycemic control in individuals with type 2 diabetes mellitus (T2DM) undergoing conventional pharmacological treatment.
Leandro Augusto Almeida +4 more
wiley +1 more source
Atherosclerosis: From Pathogenesis to Therapeutic Interventions
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou +9 more
wiley +1 more source
ABSTRACT Purpose SGLT2 inhibitors (SGLT2i) and GLP‐1 receptor agonists (GLP‐1 RA) provide cardiovascular (CV) benefits, but their first‐line use among adults with severe mental illness (SMI) is not well characterized. We evaluated selective prescribing of SGLT2i, GLP‐1 RA, and metformin among adults with SMI and type 2 diabetes (T2D).
Yueh‐Yi Chiang +5 more
wiley +1 more source
Single channel study of the spasmodic mutation α1A52S in recombinant rat glycine receptors [PDF]
Inherited defects in glycine receptors lead to hyperekplexia, or startle disease. A mutant mouse, spasmodic, that has a startle phenotype, has a point mutation (A52S) in the glycine receptor α1 subunit.
Colquhoun, D. +3 more
core
Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11971-11977, December 2026.
Bingyu Zhang +9 more
wiley +1 more source
Exercise may mitigate diabetic cardiomyopathy by improving mitochondrial metabolism, redox balance, calcium handling, and inflammatory‐fibrotic remodeling. Translation into clinical practice requires phenotype‐ and risk‐adapted exercise prescriptions, standardized dose reporting, and multimodal monitoring to define safety, efficacy, and long‐term ...
Xiaoya Li, Zhiqiang Wang, Jingjing Liu
wiley +1 more source
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert +12 more
wiley +1 more source

